Astella’s Veoza Received Positive Opinion from EU’s CHMP for the treatment of VMS associated with Menopause
Shots:
- The EMA’s CHMP has adopted a positive opinion recommending the use of Veoza (fezolinetant) 45 mg QD for the treatment of moderate to severe vasomotor symptoms (VMS) also known as hot flashes and/or night flashes associated with menopause. The EC’s decision is expected by YE 2023
- The positive opinion was adopted based on 3 P-III studies from BRIGHT SKY Program which included (SKYLIGHT 1), (SKYLIGHT 2) & (SKYLIGHT 4) evaluating the safety & efficacy of Veoza (fezolinetant) to treat patients (n=3000) suffering from moderate to severe VMS-associated with menopause
- Fezolinetant is a selective neurokinin-3 (NK3) receptor antagonist, which blocks NKB by binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron, helping restore the balance in the brain’s temperature control center (the hypothalamus) to reduce the number and intensity of hot flashes and night sweats
Ref: Astellas | Image: Astellas
Related News:- Astellas’ Veozah (fezolinetant) Receives the US FDA’s Approval for the Treatment of Vasomotor Symptoms Due to Menopause
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
